Androgel makers fight for FTC to be cross-appellant
AbbVie and Besins Healthcare say they want the Federal Trade Commission to be designated the cross-appellant because this would be logical, not because it would limit the extent to which the agency could brief its side of the sham litigation case.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is a leading global provider of competition law, regulation and enforcement information, combining data, deep market insight and a user-centric platform to provide our clients with powerful legal solutions.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10